Reply: Antithrombotic Regimen in Post-TAVR Atrial Fibrillation: Not an Easy Decision

JACC Cardiovasc Interv. 2016 Nov 28;9(22):2366-2368. doi: 10.1016/j.jcin.2016.09.038.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Anticoagulants
  • Atrial Fibrillation*
  • Fibrinolytic Agents
  • Humans
  • Risk Factors
  • Stroke
  • Transcatheter Aortic Valve Replacement*
  • Warfarin

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Warfarin